The Drugs for Neglected Diseases initiative (DNDi) has issued a call for nominations for a new Board member who is a specialist in legal issues and ethics.
DNDi is an independent, not-for-profit foundation registered under the Swiss Civil Code, administered by a Board of Directors (the Board). Board members are experts in their field and are chosen for their commitment to the public interest, their technical competency, and their support of the mission of DNDi. The Board has powers over all matters pertaining to DNDi, notably, approving the overall policies and principles of DNDi, including those related to ethical considerations and fundraising strategies; approving project selection; and adopting the annual work plan and budget.
Board members are selected from areas of expertise including (but not limited to) pharma/biotech research and development and related science, business development, clinical development, public health, fundraising, finance, legal, and global health communications and advocacy. The Board currently has twelve members. The Board is seeking to enhance its competencies with the addition of a Board member who is a specialist in law and ethics, preferably with human resources knowledge and, if possible, with a civil society background.
Board memberships are for a term of four years and a maximum of three consecutive terms (twelve years total). Board members serve in an honorary capacity and are allowed reimbursement for reasonable expenses related to their work with DNDi, including travel expenses.
The closing date for applications is 23 September 2019.
Established in 2003, the Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit research and development (R&D) organization that develops new, improved, and affordable medicines for deadly neglected diseases that afflict millions of the world’s poorest people. DNDi focuses on discovering and developing treatments for sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception, DNDi has developed seven new treatments for neglected patients and has developed a robust R&D pipeline including new drug candidates. www.dndi.org